VALERIE BOTSCHELLER: Open Payments
NPI 1649781030 · BERLIN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,638 in 149 payments from 18 companies in 2025. Trend: 2023 $2,844 · 2024 $3,844 · 2025 $3,638
Food & beverage: $3,638
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $761 |
| Janssen Biotech, Inc. | 15 | $599 |
| QOL Medical, LLC | 21 | $532 |
| Phathom Pharmaceuticals, Inc. | 25 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $249 |
| Regeneron Healthcare Solutions, Inc. | 9 | $190 |
| Madrigal Pharmaceuticals | 5 | $185 |
| GENZYME CORPORATION | 7 | $172 |
| Novo Nordisk Inc | 3 | $159 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $135 |
Products named: TREMFYA, Sucraid, DUPIXENT, VOQUEZNA, SKYRIZI, MAVYRET, ENTYVIO, REZDIFFRA.
Industry payments across MD — which companies pay providers there.
